Evaluation of 5-(2-(4-pyridinyl)vinyl)-6-chloro-3-(1-methyl-2-(S)- pyrrolidinylmethoxy)pyridine and its analogues as PET radioligands for imaging nicotinic acetylcholine receptors

Journal of Neurochemistry

Volumn 91, Issue 3, 2004, Pages 600-612

  Brown, LaVerne ^a,b   Chefer, Svetlana ^a   Pavlova, Olga ^a   Vaupel, D Bruce ^a   Koren, Andrei O ^a,c   Kimes, Alane S ^a   Horti, Andrew G ^a   Mukhin, Alexey G ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b HOWARD UNIVERSITY   (United States)

^c Inst for Neurodeg Disorders   (United States)

Author keywords

Nicotinic acetylcholine receptor; Positron emission tomography; Receptor binding

Indexed keywords

2 CHLORO 5 [(1 METHYL 2 PYRROLIDINYL)METHOXY 3 [2 (2 PYRIDINYL)VINYL] PYRIDINE]; 2 CHLORO 5 [1 (METHYL 2 AZETIDINYL)METHOXY 3 [2 (4 PYRIDINYL)VINYL] PYRIDINE]; 2 CHLORO 5 [1 (METHYL 2 PYRROLIDINYL)METHOXY 3 [2 (2 PYRIDINYL)VINYL] PYRIDINE]; 2 CHLORO 5 [1 (METHYL 2 PYRROLIDINYL)METHOXY 3 [2 (3 PYRIDINYL)VINYL] PYRIDINE]; 2 FLUORO 3 (2 AZETIDINYLMETHOXY)PYRIDINE; 5 [2 (4 PYRIDINYL)VINYL] 6 CHLORO 3 (1 METHYL 2 PYRROLIDINYLMETHOXY) PYRIDINE; CARBON 11; FLUORINE 18; NICOTINIC RECEPTOR; PYRIDINE DERIVATIVE; RADIOLIGAND; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATAXIA; BINDING ASSAY; BRAIN; BREATHING DISORDER; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; DRUG SCREENING; HYPOTHERMIA; ISOTOPE LABELING; LIPOPHILICITY; MALE; MONKEY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR BINDING; RESPIRATORY DISTRESS; SEIZURE;

ANIMALS; AZETIDINES; BINDING, COMPETITIVE; BRAIN; CARBON RADIOISOTOPES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; MACACA MULATTA; MALE; MICE; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; PYRROLIDINES; RATS; RECEPTORS, NICOTINIC;

ANIMALIA;

EID: 7244248992     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02762.x     Document Type: Article

References (65)

1. Adler L. E., Hoffer L. J., Griffith J., Waldo M. C. and Freedman R. (1992) Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol. Psychiatry 32, 607-616.
2. 3H]nicotine binding sites in human brain. J. Neurochem. 50, 1243-1247.
3. 18F-fluoro-A-85380 in healthy volunteers. J. Nucl. Med. 44, 596-601.
4. 3H]nicotine binding in human postmortem brain. J. Pharmacol. Exp. Ther 282, 7-13.
5. 3H]1-nicotine in the mouse brain. Life Sci. 44, 1123-1132.
6. 11C] methyl-2-(S)-pyrrolidinylmethoxy) pyridine, a high affinity ligand for studying nicotinic acetylcholine receptors by positron emission tomography. Bioorg. Med. Chem. 9, 3055-3058.
7. Brown L. L., Kulkarni S., Pavlova O. A., Koren A. O., Mukhin A. G., Newman A. H. and Horti A. G. (2002) Synthesis and evaluation of a novel series of 2-chloro-5-(1-methyl-2-(S)-pyrrolidinyl) methoxy)-3-(2-(4-pyridinyl) vinyl) pyridine analogues as potential positron emission tomography imaging agents for nicotinic acetylcholine receptors. J. Med. Chem. 45, 2841-2849.
8. 123I]iodo- A-85380 using single photon emission computed tomography. Life Sci. 63, L355-L360.
9. 18F]F-A-85380: a PET radioligand for α4β2 nicotinic acetylcholine receptors. Neuroreport 10, 2715-2721.
10. 18F]Fluoro-A- 85380: a novel PET ligand for nicotinic acetylcholine receptors. Proceedings of the International Conference on Mathematics and Engineering Techniques in Medicine and Biological Sciences. 6-26. Valafar F. (ed.) II, pp. 409-415. CSREA Press, Las Vegas, NV.
11. 18F]FA binding to nicotinic acetylcholine receptors in rhesus monkey brain. Synapse 48, 25-34.
12. Cimino M., Marini P., Fornasari D., Cattabeni F. and Clementi F. (1992) Distribution of nicotinic receptors in cynomolgus monkey brain and ganglia: localization of α3 subunit mRNA, α-bungarotoxin and nicotine binding sites. Neuroscience 51, 77-86.
13. Collins A. C., Luo Y., Selvaag S. and Marks M. J. (1994) Sensitivity to nicotine and brain nicotinic receptors are altered by chronic nicotine and mecamylamine infusion. J. Pharmacol. Exp. Ther. 271, 125-133.
14. Ding Y. S., Gatley S. J., Fowler J. S., Volkow N. D., Aggarwal D., Logan J., Dewey S. L., Liang F., Carroll F. I. and Kuhar M. J. (1996) Mapping nicotinic acetylcholine receptors with PET. Synapse 24, 403-407.
15. 18F]norchlorofluoroepibatidine and its N-methyl derivative: new PET ligands for mapping nicotinic acetylcholine receptors. J. Labelled Cpd. Radiopharm. 39, 827-832.
16. Dolci L., Dollé F., Valette H., Vaufrey F., Fuseau C., Bottlaender M. and Crouzel C. (1999) Synthesis of a fluorine-18 labeled derivative of epibatidine for in vivo nicotinic acetylcholine receptor PET imaging. Bioorg. Med. Chem. 7, 467-479.
17. 18F]fluoro-3-[2(S)- 2-azetidinylmethoxy]pyridine, a highly potent radioligand for in vivo imaging central nicotinic acetylcholine receptors. J Labelled Cpd. Radiopharm. XLI, 451-463.
18. Dollé F., Dolci L., Valette H., Hinnen F., Vaufrey F., Guenther I., Fuseau C., Coulon C., Bottlaender M. and Crouzel C. (1999) Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors. J. Med. Chem. 42, 2251-2259.
19. Durany N., Zochling R., Boissl K. W., Paulus W., Ransmayr G., Tatschner T., Danielczyk W., Jellinger K., Deckert J. and Riederer P. (2000) Human post-mortem striatal α4β2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. Neurosci. Lett. 287, 109-112.
20. 11C]raclopride binding to D2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. J. Cereb. Blood Flow Metab. 9, 696-708.
21. 3H] cytisine. Life Sci. 54, 1883-1890.
22. Flores C. M., DeCamp R. M., Kilo S., Rogers S. W. and Hargreaves K. M. (1996) Neuronal nicotinic receptor expression in sensory neurons of the rat trigeminal ganglion: demonstration of α3β4, a novel subtype in the mammalian nervous system. J. Neurosci. 16, 7892-7901.
23. Gunn R. N., Lammertsma A. A., Hume S. P. and Cunningham V. J. (1997) Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6, 279-287.
24. Han Z. Y., Zoli M., Cardona A., Bourgeois J. P., Changeux J. P. and Le Novere N. (2003) Localization of [3H]nicotine, [3H]cytisine, [3H]epibatidine, and [125I]α-bungarotoxin binding sites in the brain of Macaca mulatta. J. Comp. Neurol. 461, 49-60.
25. Holladay M. W., Dart M. J. and Lynch J. K. (1997) Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J. Med. Chem. 40, 4169-4194.
26. 18F]fluoro-5-pyridyl)-7-azabicyclo[2.2.1]heptane. J. Labelled Cpd. Radiopharm. XXXVIII, 355-365.
27. Horti A., Scheffel U., Stathis M., Finley P., Ravert H. T., London E. D. and Dannals R. F. (1997) Fluorine-18-FPH for PET imaging of nicotinic acetylcholine receptors. J. Nucl. Med. 38, 1260-1265.
28. 18FA-85380). J. Labelled Cpd. Radiopharm. 41, 309-318.
29. 18F]Fluoro-A-85380, an in vivo tracer for the nicotinic acetylcholine receptors. Nucl. Med. Biol. 25, 599-603.
30. 123/125I]iodo-3-(2(S)-azetidinylmethoxy) pyridine: a radioligand for nicotinic acetylcholine receptors. Nucl. Med. Biol. 26, 175-182.
31. Ichise M., Ballinger J. R., Golan H., Vines D., Luong A., Tsai S. and Kung H. F. (1996) Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT. J. Nucl. Med. 37, 513-520.
32. Ichise M., Meyer J. H. and Yonekura Y. (2001) An introduction to PET and SPECT neuroreceptor quantification models. J. Nucl. Med. 42, 755-763.
33. 18F]F-A-85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. FASEB J. 17, 1331-1333.
34. Koren A. O., Horti A. G., Mukhin A. G., Gündisch D., Kimes A. S., Dannals R. F. and London E. D. (1998) 2-, 5-, and 6-Halo-3-(2(S)- azetidinylmethoxy) pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling. J. Med. Chem. 41, 3690-3698.
35. Kulak J. M., Sum J., Musachio J. L., McIntosh J. M. and Quik M. (2002) 5-Iodo-A-85380 binds to α-conotoxin MII-sensitive nicotinic acetylcholine receptors (nAChRs) as well as α4β2* subtypes. J. Neurochem. 81, 403-406.
36. Lammertsma A. A. and Hume S. P. (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4, 153-158.
37. 11C]raclopride studies. J. Cereb. Blood Flow Metab. 16, 42-52.
38. Liang F., Navarro H. A., Abraham P., Kotian P., Ding Y. S., Fowler J. S., Volkow N. D., Kuhar M. J. and Carroll F. I. (1997) Synthesis and nicotinic acetylcholine receptor binding properties of exo-2-(2′-fluoro-5′- pyridinyl)-7-azabicyclo-[2.2.1]heptane: a new positron emission tomography ligand for nicotinic receptors. J. Med. Chem. 40, 2293-2295.
39. Lin N. H., He Y., Holladay M. W., Ryther K. and Li Y. (1997) 3-Pyridyloxymethyl Heterocyclic Ether Compounds Useful in Controlling Chemical Synaptic Transmission. US Patent 5,629,325.
40. Logan J., Fowler J. S., Volkow N. D., Wang G. J., Ding Y. S. and Alexoff D. L. (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab. 16, 834-840.
41. Lukas R. J., Changeux J. P., Le Novere N. et al. (1999) International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol. Rev. 51, 397-401.
42. Molina P. E., Ding Y. S., Carroll F. I., Liang F., Volkow N. D., Pappas N., Kuhar M., Abumrad N., Galley S. J. and Fowler J. S. (1997) Fluoro-norchloroepibatidine: preclinical assessment of acute toxicity. Nucl. Med. Biol. 24, 743-747.
43. Mukhin A. G., Chefer S. I., Horti A. G. et al. (2000a) Radiohalogenated analogs of A-85380 as potential ligands for in vivo monitoring of the α4β2 nicotinic receptor alteration in Alzheimher's disease. Proceedings of the International Conference on Mathematics and Engineering Techniques in Medicine and Biological Sciences. 6-26. Valafar F. (ed.) II, pp. 429-435. CSREA Press, Las Vegas.
44. Mukhin A. G., Gundisch D., Horti A. G. et al. (2000b) 5-Iodo-A-85380, an α4β2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol. Pharmacol. 57, 642-649.
45. 125/123I]IPH: a radioiodinated analog of epibatidine for in vivo studies of nicotinic acetylcholine receptors. Synapse 26, 392-399.
46. Newhouse P. A. and Kelton M. (2000) Nicotinic systems in central nervous systems disease: degenerative disorders and beyond. Pharm. Acta Helv. 74, 91-101.
47. Paterson D. and Nordberg A. (2000) Neuronal nicotinic receptors in the human brain. Prog. Neurobiol. 61, 75-111.
48. Patt J. T., Spang J. E., Westera G., Buck A. and Schubiger P. A. (1999) Synthesis and in vivo studies of [C-11]N-methylepibatidine: comparison of the stereoisomers. Nucl. Med. Biol. 26, 165-173.
49. Pavlova O. A., Koren A. O., Horti A. G., Gündisch D., London E. D., Kimes A. S. and Mukhin A. G. (2001) Effect of temperature on interacton between ligands and α4β2 nicotinic receptors. Soc. Neurosci. Abstr. 27, 485.1.
50. Perry E. K., Haroutunian V., Davis K. L. et al. (1994) Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 5, 747-749.
51. Perry D. C., Dávila-García M. I., Stockmeier C. A. and Kellar K. J. (1999) Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J. Pharmacol. Exp. Ther. 289, 1545-1552.
52. 125I-α-conotoxin MII binding sites to nigrostriatal damage in monkey. J. Neurosci. 21, 5494-5500.
53. Sanberg P. R., Silver A. A., Shytle R. D., Philipp M. K., Cahill D. W., Fogelson H. M. and McConville B. J. (1997) Nicotine for the treatment of Tourette's syndrome. Pharmacol. Ther. 74, 21-25.
54. Spang J. E., Patt J. T., Westera G. and Schubiger P. A. (2000) Comparison of N-[11C]methyl-norchloroepibatidine and N-[11C]methyl-2-(2-pyridyl)-7- azabicyclo[2.2.1]heptane with N-[11C]methylepibatidine in small animal PET studies. Nucl. Med. Biol. 27, 239-247.
55. Steinlein O. K., Mulley J. C., Propping P., Wallace R. H., Phillips H. A., Sutherland G. R., Scheffer I. E. and Berkovic S. F. (1995) A missense mutation in the neuronal nicotinic acetylcholine receptor α4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat. Genet 11, 201-203.
56. Swanson L. W., Simmons D. M., Whiting P. J. and Lindstrom J. (1987) Immunohistochemical localization of neuronal nicotinic receptors in the rodent central nervous system. J. Neurosci. 7, 3334-3342.
57. 18F]fluoro-3-[2(S)-2-azetidinylmethoxy] pyridine in vivo. Life Sci. 64, PL93-PL97.
58. 18F]fluoro-A-85380. J. Nucl. Med. 40, 1374-1380.
59. Valette H., Dollé F., Bottlaender M., Hinnen F. and Marzin D. (2002) Fluoro-A-85380 demonstrated no mutagenic properties in in vivo rat micronucleus and Ames tests. Nucl. Med. Biol. 29, 849-853.
60. Valette H., Bottlaender M., Dollé F., Coulon C., Ottaviani M. and Syrota A. (2003) Long-lasting occupancy of central nicotinic acetylcholine receptors after smoking: a PET study in monkeys. J. Neurochem. 84, 105-111.
61. 125I]5-I-A-85380, a nicotinic acetylcholine receptor radioligand. Neuroreport 9, 2311-2317.
62. Vaupel D. B., London E. D., Horti A. G. et al. (2002) 2[F-18]F-A-85380 acquires phase 1 approval as a radiotracer for imaging α4β2 nicotinic receptors in human PET studies. Drug Alcohol Depend. Suppl. 1, S187.
63. Villemagne V. L., Horti A., Scheffel U., Ravert H. T., Finley P., Clough D. J., London E. D., Wagner H. N. Jr and Dannals R. F. (1997) Imaging nicotinic acetylcholine receptors with fluorine-18-FPH, an epibatidine analog. J. Nucl. Med. 38, 1737-1741.
64. 2 receptors. J. Pharmacol. Exp. Ther. 291, 409-415.
65. 125I-alpha-conotoxin MII identifies a novel nicotinic acetylcholine receptor population in mouse brain. Mol. Pharmacol. 57, 913-925.